Moderate

Congenital (TORCH) infections — neonatal approach

SGA, rash, calcifications · Paediatric
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Congenital infections (toxoplasmosis, other [syphilis, VZV, parvovirus], rubella, CMV, HSV) are acquired in utero and share overlapping features — growth restriction, hepatosplenomegaly, jaundice, rash, thrombocytopenia, and CNS/eye/hearing involvement. CMV is the commonest; the approach is to recognise the pattern, identify the organism, and treat where effective therapy exists.

Red flags

  • Microcephaly, seizures or abnormal neuro-imaging
  • Thrombocytopenia with petechiae/purpura ('blueberry muffin' rash)
  • Conjugated hyperbilirubinaemia and hepatosplenomegaly
  • Vesicular rash or sepsis (consider HSV — treat empirically)
  • Failed newborn hearing screen

Assessment

Differential diagnosis

  • Congenital CMV
  • Congenital toxoplasmosis
  • Congenital rubella syndrome
  • Congenital syphilis
  • Neonatal HSV / congenital varicella
  • Early-onset bacterial sepsis (mimic)

Investigations

  • Congenital CMV: urine/saliva CMV PCR within the first 21 days of life (diagnostic window)
  • Toxoplasma, rubella, syphilis (VDRL/TPPA) serology on infant and mother
  • FBC, LFTs, conjugated bilirubin, coagulation
  • Cranial ultrasound/MRI (calcifications, ventriculomegaly, migration anomalies)
  • Ophthalmology review (chorioretinitis, cataract) and formal hearing screen (AABR)
  • Lumbar puncture/CSF and long-bone X-rays where syphilis or specific organism suspected

Management

  • Suspect congenital infection in any growth-restricted or symptomatic neonate with multisystem signs
  • Send targeted virology/serology, prioritising CMV PCR before 21 days of age
  • Image the brain and arrange ophthalmology and audiology assessment
  • Check platelets, liver function and coagulation
  • Confirm the specific organism before committing to prolonged therapy
  • Treat symptomatic congenital CMV with oral valganciclovir (or IV ganciclovir) for 6 months with blood monitoring
  • Treat congenital toxoplasmosis with pyrimethamine + sulfadiazine + folinic acid for ~12 months
  • Treat congenital syphilis with IV/IM penicillin per staging
  • Arrange long-term audiology and neurodevelopmental follow-up (progressive hearing loss in CMV)
  • Involve maternal/infectious diseases services and discuss prevention in future pregnancies

Drugs & doses

Valganciclovir 16 mg/kg/dose PO twice daily for 6 months (symptomatic congenital CMV); IV ganciclovir 6 mg/kg/dose 12-hourly if enteral not tolerated
Pyrimethamine + sulfadiazine + folinic acid (calcium folinate) for congenital toxoplasmosis (~12 months)
Benzylpenicillin 50 mg/kg/dose IV (frequency by age) for 10 days for congenital syphilis
Aciclovir 20 mg/kg/dose IV 8-hourly if neonatal HSV suspected

Disposition

Neonatal unit/outpatient work-up with infectious diseases input; start organism-specific therapy. Enrol in long-term audiology, ophthalmology and neurodevelopmental follow-up.

Complications & pitfalls

  • Sensorineural hearing loss (often progressive, especially CMV)
  • Neurodevelopmental impairment and epilepsy
  • Visual impairment from chorioretinitis/cataract
  • Hydrops/anaemia (parvovirus)
  • Bleeding from thrombocytopenia

Exam pearls

  • CMV PCR must be collected within the first 3 weeks of life to prove congenital (vs postnatal) infection
  • Antiviral treatment of symptomatic CMV improves hearing and neurodevelopmental outcomes
  • A vesicular rash or sepsis-like picture should trigger empirical HSV therapy while testing
  • All suspected congenital infections need audiology and ophthalmology surveillance

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.